Compare NBTB & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | RCKT |
|---|---|---|
| Founded | 1856 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 340.9M |
| IPO Year | N/A | N/A |
| Metric | NBTB | RCKT |
|---|---|---|
| Price | $41.57 | $3.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $51.00 | $29.12 |
| AVG Volume (30 Days) | 220.8K | ★ 1.9M |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ 5.89 | N/A |
| EPS | ★ 3.02 | N/A |
| Revenue | ★ $629,728,000.00 | N/A |
| Revenue This Year | $27.08 | N/A |
| Revenue Next Year | $9.17 | N/A |
| P/E Ratio | $13.75 | ★ N/A |
| Revenue Growth | ★ 16.88 | N/A |
| 52 Week Low | $37.31 | $2.19 |
| 52 Week High | $49.18 | $13.35 |
| Indicator | NBTB | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 55.55 |
| Support Level | $43.70 | $3.36 |
| Resistance Level | $42.91 | $3.60 |
| Average True Range (ATR) | 0.83 | 0.18 |
| MACD | -0.31 | 0.01 |
| Stochastic Oscillator | 3.88 | 76.09 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.